Predilife
Research Predilife (ALPRE) on Bullrun: market cap EUR 4.41M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALPRE
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyEUR
- Market capEUR 4.41M
- Financial periodFY2025
- RevenueEUR 1.12M
- Revenue growth80.9%
- Net income-EUR 3.52M
- Free cash flow-EUR 2.57M
- Gross margin98.9%
Valuation Snapshot
latest market cap is EUR 4.41M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.12M | -EUR 3.52M | -EUR 2.57M | 98.9% | -1 | EUR 556.92K | EUR 5.52M | -EUR 6.91M |
| FY2024 | EUR 618.06K | EUR 198.63M | -EUR 3.73M | 97.8% | n/a | EUR 1.06M | EUR 4.95M | -EUR 4.27M |
| FY2023 | EUR 317.83K | -EUR 4.22M | -EUR 4.27M | 96.6% | -1.14 | EUR 2.51M | EUR 7.43M | -EUR 3.92M |
| FY2022 | EUR 288.68K | -EUR 3.65M | -EUR 3.09M | 87.5% | -1 | EUR 3.72M | EUR 7.09M | EUR 956.99K |
| FY2021 | EUR 142.67K | -EUR 3.40M | -EUR 3.83M | 65.4% | -0.93 | EUR 2.82M | EUR 5.13M | -EUR 1.57M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 4.41M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Predilife's market cap?
Predilife's market capitalization is EUR 4.41M.
What does Predilife do?
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer prediction test based on the patient's individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and is headquartered in Villejuif, France.